Elanco Animal Health vs IDEXX Laboratories
ELAN and IDXX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELAN and IDXX compare
IDEXX Laboratories is the larger company, worth 3.8 times as much as Elanco Animal Health ($43.4B against $11.5B).
IDEXX Laboratories grew revenue faster over the last twelve months (12.8% versus 12.0% for Elanco Animal Health).
IDEXX Laboratories keeps more of each dollar of sales as profit, with a net margin of 25.0% compared with −4.0% at Elanco Animal Health.
IDEXX Laboratories scores higher on the StockData Score (19 against 9 for Elanco Animal Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELAN | IDXX |
|---|---|---|
| Size and price | ||
| Market cap | $11.5B | $43.4B |
| Share price | $23.06 | $551.21 |
| Change, 1 year | 2.1% | −12.2% |
| Change, 5 years | −32.4% | −13.5% |
| Beta (5Y) | 1.11 | 1.22 |
| Employees | 9,400 | 11K |
| StockData Score | ||
| Total score | 9 | 19 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 3 | 5 (better) |
| Performance score | 3 | 6 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 38.8× |
| P/S | 2.3× (better) | 9.5× |
| P/B | 1.7× (better) | 26.9× |
| EV/EBITDA | 28.3× | 27.1× (better) |
| P/FCF | 30.4× (better) | 34.6× |
| PEG | – | 2.19 |
| FCF yield | 3.3% (better) | 2.9% |
| Fair value | $10.92 | $507.90 |
| Margin of safety | −111% | −8.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.0% | 12.8% (better) |
| Revenue growth, 5Y average | 7.6% | 9.7% (better) |
| Net income growth (TTM) | −146% | 15.6% (better) |
| EPS growth (TTM) | −149% | 18.4% (better) |
| EPS growth, 5Y average | – | 14.3% |
| Profitability | ||
| Gross margin | 55.4% | 62.4% (better) |
| Operating margin | – | 32.0% |
| Net margin | −4.0% | 25.0% (better) |
| FCF margin | 7.5% | 27.5% (better) |
| Return on equity | −3.0% | 74.2% (better) |
| Return on invested capital | – | 63.3% |
| Financial health | ||
| Debt / equity | 0.59 | 0.28 (better) |
| Net debt / EBITDA | 6.43 | 0.16 (better) |
| Interest coverage | – | 38.6× |
| Current ratio | 2.05 (better) | 1.17 |
| Altman Z-score | 1.32 | 19.89 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 2.7% |
| Shareholder yield | 0.00% | 2.7% (better) |
| Ownership | ||
| Held by institutions | 113% | 94.5% |
| Held by insiders | 1.1% | 0.30% |
| Insider net buying, 12 months | $2.6M (better) | −$37.7M |
| Superinvestors holding | – | 3 |
| Short interest, % of float | 7.5% | 2.5% |
Go deeper
- ELAN stock overview
- ELAN income statement
- ELAN valuation and score
- IDXX stock overview
- IDXX income statement
- IDXX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.